Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01494324 · ClinicalTrials.gov registry record · NA

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

A NA study of Liver Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT01494324: Active NA study of Liver Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01494324 is a NA study of Liver Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 150 participants, below the 446-participant average among 78 other Liver Cancer trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01494324, a NA study of Liver Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if the investigators can do some tests on tissue from the area of the ablation. The investigators want to know if a test can help predict whether the ablation worked. The treated tumor is normally evaluated with CT. The CT shows signs of treated tumor(s) in the area treated by ablation. However, cancer cells may begin to grow in or near the treated area. The CT scan cannot tell us if the cells are new cancer cells or if they are healthy liver cells that just look different because of the ablation. The test the investigators will study should be able to tell us the difference.

Primary Outcome

will be measured according to EASL and RECIST. In the case of differences between these criteria, the EASL criteria will be used for clinical judgment and decisions.Tumor response will be determined at the discretion of the Principal Investigator in the case of overlapping ablation zones or lesions seen only in PET.

Conditions Studied

Interventions

  • OTHER CT guided percutaneous ablation

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2009-10-27
Est. Completion 2026-10
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT01494324 still lists

NCT01494324 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 78 other Liver Cancer trials with a reported enrollment target (66% lower).

The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which CT guided percutaneous ablation is the first listed.

NCT01494324 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01494324 about?

NCT01494324 is a clinical study titled "Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome". The purpose of this study is to see if the investigators can do some tests on tissue from the area of the ablation. The investigators want to know if a test can help predict whether the ablation worked. The treated tumor is normally evaluated with CT. The CT shows signs of treated tumor(s) in the a...

What is the current status of trial NCT01494324?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2009-10-27. Estimated completion is 2026-10.

What conditions does trial NCT01494324 study?

This clinical trial studies the following conditions: Liver Cancer.

What interventions are being tested in trial NCT01494324?

The interventions under investigation include: CT guided percutaneous ablation (OTHER).

Who is sponsoring clinical trial NCT01494324?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01494324 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01494324's enrollment target sits among peer trials

150 21st of 78 higher than 58 of 78 other Liver Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01494324, the US trial registry maintained by the National Library of Medicine. NCT01494324 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.